Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HG 204

Next Previous
X
Search
Drug Profile

HG 204

Alternative Names: AAV-hfCas13Y-gMECP2; HG-204

Latest Information Update: 07 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HuidaGene Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene silencing; Methyl-CpG-binding protein 2 expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lubs X-linked mental retardation syndrome
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Lubs X-linked mental retardation syndrome; Neurodegenerative disorders

Most Recent Events

  • 26 Sep 2024 HuidaGene Therapeutics plans the HERO clinical trial for Lubs X linked mental retardation syndrome (Treatment-experienced, In Adolescents, In children) in November 2024 (Intracerebral, Injection) (NCT06615206)
  • 29 May 2024 HG 204 receives Orphan Drug status for Lubs X-linked mental retardation syndrome in European Union, prior to May 2024
  • 31 Oct 2023 Preclinical trials in Lubs X-linked mental retardation syndrome in China (Parenteral)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top